Total Funding
34
52
Total FundingPost-IPO Debt raised
Growth Score
-3 pts
Heat Score
-30 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
81609
Radius Health develops drug therapies for osteoporosis and women’s health.
Acquired by 
Paratek Pharmaceuticals
Barry Holtz: CEO
John A. Katzenellenbogen: Founder
About the Company
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
